Positive initiatives in therapeutic areas
At Consilient Health, innovative solutions for patient health are our focus.
We offer a wide variety of prescription medicines, including a licensed vitamin D range and products in women’s health, urology, smoking cessation and child mental health. We partner with the NHS to drive the reliable provision of high-quality medicines and cost-savings for the NHS, complemented by comprehensive support programs for both medical professionals and patients.
For access to the summary of product characteristics, patient information leaflets, and available risk minimisation measures, please view the product section below.
Women’s Health
Consilient Health continue to invest in market leading therapies for our women’s health portfolio. We always look to build in value for both healthcare professionals and patients.
We have a Hormone Replacement Therapy (HRT) gel for vaginal atrophy for women with the menopause and we continue to provide educational resources for both patients and healthcare professionals in this important therapy area.
Endocrinology Portfolio Information
Since launching our first endocrinology product in 2014, Consilient Health has successfully launched products in this therapeutic area including medicines to optimise bone health and diagnose rare conditions. These are managed by our UK, Irish and European specialty business units.
We provide a range of bone health products that meet prescribers’ and patients’ needs. Providing innovative solutions for prescribers and patients is a key element of our offering.
Consilient Health is a valued strategic partner with plans to continue its expansion in this area over the coming years.
Urology
Consilient Health is proud to have brought to market a specialist urology product used to treat a rare and potentially debilitating urological condition. The disease is poorly understood and treatment options are limited.
Consilient Health was successful in gaining a positive appraisal from NICE and SMC in 2019. This is in keeping with our desire to bring to the market medicines that have a clear differentiation and where there is an unmet clinical need.
ADHD
Consilient Health is proud to have launched an innovative formulation of an existing treatment for ADHD.
This latest addition to our portfolio underscores our commitment to diversifying treatment options and enhancing the patient experience.
Recognising the varied needs of young patients. This launch aligns with our dedication to meeting the evolving needs in healthcare, continually seeking to improve patient choice and accessibility in ADHD therapy.
Smoking
Smoking is the UK’s biggest preventable killer – causing around 1 in 4 cancer deaths and leading to 64,000 deaths per year in England. It is also one of the biggest drivers of health inequalities across the country, and tackling this is a priority to improve public health.
Consilient Health is proud to invest in this area of significant unmet need and remains dedicated to bringing forward treatments that can make a real difference in people’s lives.
Products